Google
CGEN 株価分析 — COMPUGEN (Healthcare >> Biotechnology)
CGEN に関するよくある質問
CGENのPER（株価収益率）は？
COMPUGEN（CGEN）は現在PER 3.89倍で取引されています。
CGENのROE（自己資本利益率）は？
COMPUGENのROEは36.55%です。
CGENの配当利回りは？
COMPUGENの配当利回りは0.00%です。
CGENの品質スコア（Quality Score）は？
当社のAIはCGENの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CGENは今が買い時ですか？
当社AIのタイミングスコアは100点中94点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CGENはどのセクターに属しますか？
COMPUGENはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
CGEN AI Analysis Summary
Our AI summary for CGEN: COMPUGEN (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.89, ROE of 36.55%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 94/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.35
Price
0.02
(0.64%)
Day Change
|
|
|---|
CGEN, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.12 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
63
GOOD
|
| Magic Formula Rank by ROE |
63
GOOD
|
| Magic Formula Rank by ROIC |
52
GOOD
|
| Price | 2.35 |
| PBV / Sector |
2.32 / 5.20
|
| Earning Per Share | 0.37 |
| PE / Sector |
3.89 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
-0.03 / 1.22
|
| Average 1M Daily Value |
0.56 M
GREAT
|
| Average 1W Daily Value |
0.46 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:38 |
| Symbol | CGEN |
| Name | COMPUGEN |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 94.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 220.86 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Azrieli Center, Holon, Israel, 5885849
Phone: 972 3 765 8585
Website: https://cgen.com
Employees: 75
Sector: Healthcare >> Biotechnology
Description: Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
